Literature DB >> 23529451

miR-221/222: promising biomarkers for breast cancer.

Wei-Xian Chen1, Qing Hu, Man-Tang Qiu, Shan-Liang Zhong, Jin-Jin Xu, Jin-Hai Tang, Jian-Hua Zhao.   

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs of 19-25 nt that can regulate gene expression at a posttranscriptional level. Increasing evidence indicates that miRNAs participate in almost every step of cellular processes and are often aberrantly expressed in human cancer. miR-221 and miR-222 are two highly homologous miRNAs that always act as a gene cluster (miR-221/222) in cellular regulation and have extensively been studied in cancer network. Here, we review the role of miR-221/222 in breast cancer (BCa) development and progression: regulating proliferative signaling pathways, altering telomere and telomerase activity, avoiding cell death from tumor suppressors, autophagy and apoptosis, monitoring angiogenesis, supporting epithelial-mesenchymal transition, and even controlling cell-specific function within microenvironment. We consider that miR-221/222 act as promising biomarkers for BCa and they would offer a new way in molecular targeting cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529451     DOI: 10.1007/s13277-013-0750-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  75 in total

1.  MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Authors:  Yi Chen; Mohd Saif Zaman; Guoren Deng; Shahana Majid; Shranjot Saini; Jan Liu; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

2.  Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.

Authors:  Nobuyasu Yoshimoto; Tatsuya Toyama; Satoru Takahashi; Hiroshi Sugiura; Yumi Endo; Mai Iwasa; Yoshitaka Fujii; Hiroko Yamashita
Journal:  Breast Cancer Res Treat       Date:  2011-07-14       Impact factor: 4.872

3.  PUMA is a novel target of miR-221/222 in human epithelial cancers.

Authors:  Chunzhi Zhang; Junxia Zhang; Anlin Zhang; Yingyi Wang; Lei Han; Yongping You; Peiyu Pu; Chunsheng Kang
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

4.  MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer.

Authors:  Dawn R Cochrane; Diana M Cittelly; Erin N Howe; Nicole S Spoelstra; Erin L McKinsey; Kelly LaPara; Anthony Elias; Douglas Yee; Jennifer K Richer
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

Review 5.  miR221/222 in cancer: their role in tumor progression and response to therapy.

Authors:  M Garofalo; C Quintavalle; G Romano; C M Croce; G Condorelli
Journal:  Curr Mol Med       Date:  2012-01       Impact factor: 2.222

6.  Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival.

Authors:  Jing Shen; Marilie D Gammon; Mary Beth Terry; Patrick T Bradshaw; Qiao Wang; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  Breast Cancer Res Treat       Date:  2012-04-12       Impact factor: 4.872

Review 7.  Microenvironmental regulation of epithelial-mesenchymal transitions in cancer.

Authors:  Dingcheng Gao; Linda T Vahdat; Stephen Wong; Jenny C Chang; Vivek Mittal
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

Review 8.  Role of microRNAs in vascular diseases, inflammation, and angiogenesis.

Authors:  Carmen Urbich; Angelika Kuehbacher; Stefanie Dimmeler
Journal:  Cardiovasc Res       Date:  2008-06-11       Impact factor: 10.787

Review 9.  Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.

Authors:  Rocío García-Becerra; Nancy Santos; Lorenza Díaz; Javier Camacho
Journal:  Int J Mol Sci       Date:  2012-12-20       Impact factor: 5.923

10.  Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells.

Authors:  Elisabetta Lambertini; Andrea Lolli; Federica Vezzali; Letizia Penolazzi; Roberto Gambari; Roberta Piva
Journal:  BMC Cancer       Date:  2012-10-02       Impact factor: 4.430

View more
  43 in total

Review 1.  MicroRNA control of high-density lipoprotein metabolism and function.

Authors:  Katey J Rayner; Kathryn J Moore
Journal:  Circ Res       Date:  2014-01-03       Impact factor: 17.367

Review 2.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

3.  MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Authors:  Yue-Feng Yang; Fei Wang; Jun-Jie Xiao; Yang Song; Ying-Ying Zhao; Yan Cao; Yi-Hua Bei; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

4.  MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival.

Authors:  Zheng Xu; Yan-Qiu Yu; Yu-Zheng Ge; Jia-Geng Zhu; Meng Zhu; You-Cai Zhao; Lu-Wei Xu; Xiao-Bing Yang; Li-Guo Geng; Quan-Liang Dou; Rui-Peng Jia
Journal:  Tumour Biol       Date:  2015-05-20

5.  Diagnostic value of circulating microRNAs as biomarkers for breast cancer: a meta-analysis study.

Authors:  Zhaolei Cui; Donghong Lin; Wenfang Song; Meihuan Chen; Dan Li
Journal:  Tumour Biol       Date:  2014-10-09

6.  miR-221 inhibits autophagy and targets TP53INP1 in colorectal cancer cells.

Authors:  Dan Liao; Tong Li; Caiguo Ye; Liuyan Zeng; Huahui Li; Xingxiang Pu; Congcong Ding; Zhiwei He; Guo-Liang Huang
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447

7.  Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors.

Authors:  Robert W Tell; Curt M Horvath
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-19       Impact factor: 11.205

Review 8.  MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential.

Authors:  Wei Wang; Yun-ping Luo
Journal:  J Zhejiang Univ Sci B       Date:  2015-01       Impact factor: 3.066

9.  miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27kip1 pathway.

Authors:  Dan-Dan Wang; Su-Jin Yang; Xiu Chen; Hong-Yu Shen; Long-Ji Luo; Xiao-Hui Zhang; Shan-Liang Zhong; Jian-Hua Zhao; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2016-10-04

Review 10.  MicroRNA-224: as a potential target for miR-based therapy of cancer.

Authors:  Wei Chen; Xue-Mei Fan; Ling Mao; Jun-Ying Zhang; Jian Li; Jian-Zhong Wu; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2015-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.